Serial T2Bacteria panel versus blood culture for monitoring Staphylococcus aureus bacteraemia: clearance duration predicts deep-seated or metastatic infection and mortality - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparison of T2Bacteria Testing and Blood Cultures for Assessing Staphylococcus aureus Bacteraemia: Duration of Clearance as a Predictor of Metastatic Infection and Mortality

  • By

  • Marianna Traugott

  • Mahdi Mahmoudi

  • Cristina Groza

  • Klaus Breinbauer

  • Harald Kirschner

  • Theresa Oelschlaegel

  • David Stuecklschwaiger

  • Michelle Naegeli

  • Max Augustin

  • David Totschnig

  • Armin Marcus Bumberger

  • Christoph Wenisch

  • Alexander Zoufaly

  • Tamara Clodi-Seitz

  • August 30, 2026

Share

  • 1

    T2B is a rapid, culture-independent assay that detects bacterial DNA directly in whole blood within hours and may detect persistent bacterial DNA after blood cultures become negative.

  • 2

    Staphylococcus aureus bloodstream infection is associated with high mortality, and its incidence is increasing, largely driven by an aging population.

  • 3

    The study compared clearance duration measured by T2B and blood cultures in Staphylococcus aureus bacteraemia and evaluated associations with deep-seated or metastatic infection and clinical outcomes.

  • 4

    Participants were adults aged 18 years or older who understood and agreed to the study procedures and had S. aureus detected in a blood culture within 24 hours before study inclusion.

  • 5

    Demographic data, comorbidities, and baseline clinical parameters were collected at enrollment, with clinical outcomes assessed at discharge or death and longer-term outcomes evaluated during follow-up.

Original Source(s)

Serial T2Bacteria panel versus blood culture for monitoring Staphylococcus aureus bacteraemia: clearance duration predicts deep-seated or metastatic infection and mortality

  • by Marianna Traugott, Mahdi Mahmoudi, Cristina Groza, Klaus Breinbauer, Harald Kirschner, Theresa Oelschlaegel, David Stuecklschwaiger, Michelle Naegeli, Max Augustin, David Totschnig, Armin Marcus Bumberger, Christoph Wenisch, Alexander Zoufaly, Tamara Clodi-Seitz

  • August 30, 2026

Related Content

Droplet microfluidics with image texture quantification for detection of rare antibiotic-resistant subpopulations from bloodstream infections

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

When Obesity Meets Infection Risk

Researchers analyze data from Finnish cohorts and the UK Biobank to examine how body mass index relates to severe infections and their global burden.